The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range

@article{Horner2005TheNS,
  title={The novel suramin analogue NF864 selectively blocks P2X1 receptors in human platelets with potency in the low nanomolar range},
  author={Susanne Horner and Kirsten Menke and Caren Hildebrandt and Matthias U. Kassack and Peter Nickel and Heiko Ullmann and Martyn P Mahaut-Smith and G{\"u}nter Lambrecht},
  journal={Naunyn-Schmiedeberg's Archives of Pharmacology},
  year={2005},
  volume={372},
  pages={1-13}
}
The role of ATP-stimulated P2X1 receptors in human platelets is still unclear. They may act alone or in synergy with other pathways, such as P2Y1 or P2Y12 receptors, to accelerate and enhance calcium mobilisation, shape change and aggregation. To date very few pharmacological means of selectively inhibiting platelet P2X1 receptors have been described, although recent work has shown that suramin is a useful lead compound for the development of high-affinity P2X1 antagonists. We therefore… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

The P2X1 ion channel in platelet function.

VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The P2X1 receptor and platelet function

VIEW 4 EXCERPTS
CITES BACKGROUND

Blood cells: an historical account of the roles of purinergic signalling

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 69 REFERENCES

Purine and pyrimidine (P2) receptors as drug targets.

VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Relationship between the inhibition

VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL